Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Aurora, Colorado

This page shows live ClinicalTrials.gov search results for Aurora, Colorado, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
7450
Shown on this page
12
Current sort
Recently updated
Location scope
Aurora, CO
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Aurora, Colorado. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 421–432 of 7,450 matching trials in Aurora, CO.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Aurora

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Active, not recruiting Phase 3 Interventional

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

NCT06619236
View directory record Official record
Conditions
Platinum-resistant Ovarian Cancer
Interventions
Rina-S, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin (PLD), Gemcitabine
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older · Female only
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
72
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 5:15 AM EST
Active, not recruiting Phase 2 Interventional Results available

A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension

NCT03492177
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
selexipag (Uptravi)
Drug
Lead sponsor
Actelion
Industry
Eligibility
2 Years to 17 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
3
States / cities
Aurora, Colorado • Iowa City, Iowa • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 5:15 AM EST
Recruiting Phase 2 Interventional

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

NCT02523014
View directory record Official record
Conditions
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
Interventions
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, Abemaciclib
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
791
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 512 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 5:15 AM EST
Active, not recruiting Phase 2 Interventional

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

NCT07266441
View directory record Official record
Conditions
Multiple Myeloma
Interventions
JNJ-79635322
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
30
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 5:15 AM EST
Recruiting Phase 2Phase 3 Interventional

A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients

NCT07549321
View directory record Official record
Conditions
High-Risk Neuroblastoma
Interventions
hu1418K322A + Temozolomide + Irinotecan
Drug
Lead sponsor
Renaissance Pharma Ltd.
Industry
Eligibility
18 Months to 18 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 5:15 AM EST
Recruiting Phase 4 Interventional

Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy

NCT07637942
View directory record Official record
Conditions
HIV -1 Infection
Interventions
Every 4-week long-acting injectable cabotegravir and rilpivirine
Drug
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 5:15 AM EST
Recruiting Phase 3 Interventional

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

NCT06661720
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8
Interventions
Pembrolizumab, Tivozanib, Biospecimen Collection, MRI, Computed Tomography, Biopsy, Questionnaire Administration
Biological · Drug · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
429
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 340 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 5:15 AM EST
Recruiting Not applicable Interventional

Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-Being

NCT07628647
View directory record Official record
Conditions
Brain Cancer
Interventions
Group Self-Management Sessions, Educational Materials Only
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 5:15 AM EST
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

NCT07224672
View directory record Official record
Conditions
Amyloidosis
Interventions
Belantamab mafodotin, Cyclophosphamide, Bortezomib, Dexamethasone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 5:15 AM EST
Recruiting Phase 1 Interventional

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

NCT06095089
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
JNJ-78278343, JNJ-87189401, Apalutamide, Lutetium Lu-177 Vipivotide Tetraxetan, JNJ-101556143
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
13
States / cities
Aurora, Colorado • Atlanta, Georgia • Minneapolis, Minnesota + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 5:15 AM EST
Recruiting Phase 3 Interventional

A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

NCT05912517
View directory record Official record
Conditions
Hemolytic Disease of the Fetus and Newborn
Interventions
Nipocalimab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 5:15 AM EST
Recruiting Phase 3 Interventional

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

NCT07200830
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Lutetium Lu 177 Vipivotide Tetraxetan, Biospecimen Collection, Patient Monitoring, Computed Tomography, Bone Scan, PSMA PET Scan, MRI, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
1,524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
142
States / cities
Anchorage, Alaska • Bakersfield, California • Irvine, California + 117 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 5:15 AM EST